A meta-analysis of salicylates for type 2 diabetes mellitus

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 33, Issue 1, 2013, Pages 1-14

  Fang, Fang ^a   Lu, Yu ^a   Ma, De Lin ^a   Du, Ting Ting ^a   Shao, Shi Ying ^a   Yu, Xue Feng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

meta analysis; salicylates; type 2 diabetes mellitus

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID DERIVATIVE;

CARDIOVASCULAR DISEASE; COMORBIDITY; HUMAN; INCIDENCE; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; STATISTICS; SURVIVAL RATE; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; HUMANS; INCIDENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SALICYLATES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84873664805     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-013-1063-5     Document Type: Review

References (80)

1. Campbell RK. Type 2 diabetes: Where we are today: An overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc, 2009,49(suppl 1):s3-s9
2. Rumore MM, Kim KS. Potential role of salicylates in type 2 diabetes. Ann Pharmacother, 2010,44(7-8):1207-1221
3. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol, 2010,55(25):2878-2886
4. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care, 2004,27(suppl 1):s72-s73
5. Goldfine AB, Silver R, Aldhahi W, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci, 2008,1(1): 36-43
6. McCarty MF. Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome. Med Hypotheses, 2010,75(3): 276-281
7. Fearnley GR, Vincent CT, Chakrabarti R. Reduction of blood fibrinolytic activity in diabetes mellitus by insulin. Lancet, 1959,2(7111):1067
8. Ogaston D, McAndrew GM. Fibrinolysis in obesity. Lancet, 1964,2(7371):1205-1207
9. Grace CS, Goldrick RB. Fibrinolysis and body build. Interrelationships between blood fibrinolysis, body composition and parameters of lipid and carbohydrate metabolism. J Atheroscler Res, 1968,8(4):705-719
10. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science, 1993,259(5091): 87-91
11. Feinstein R, Kanety H, Papa MZ, et al. Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem, 1993,268(35):26 055-26 058
12. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes, 1994,43(11):1271-1278
13. Shoelson SE, LEE J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest, 2006,116(7):1793-1801
14. Ebstein W. Invited comment on W. Ebstein: On the therapy of diabetes mellitus, in particular on the application of sodium salicylate. J Mol Med, 2002,80(10):618-619
15. Williamson RT. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J, 1901,1(2100):760-762
16. Reid J, Macdougall AI, Andrews MM. Aspirin and diabetes mellitus. Br Med J, 1957,2(5053):1071-1074
17. Hecht A, Goldner MG. Reappraisal of the hypoglycemic action of acetylsalicylate. Metabolism, 1959,8(4Pt 1): 418-428
18. Gilgore SG. The influence of salicylate on hyperglycemia. Diabetes, 1960,9(5):392-393
19. Goldfine AB, Fonseca V, Jablonski KA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes. Ann Intern Med, 2010,152(6):346-357
20. Fleischman A, Bernier R, Shoelson SE. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care, 2008,31(2):289-294
21. Koska J, Ortega E, Bunt JC, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomized double-blind placebo-controlled study. Diabetologia, 2008,52(3):385-393
22. Pierce GL, Lesniewski LA, Lawson BR, et al. Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/ obese middle-aged and older humans. Circulation, 2009,119(9):1284-1292
23. Higgins JP, Altman DG. Assessing risk of bias in included studies. In: Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. 5.0.2 ed. England: John Wiley & Sons Ltd, 2008,206
24. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996,17(1):1-12
25. Deeks JJ, Higgins JP, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. 5.0.2 ed. England: John Wiley & Sons Ltd, 2008,206
26. Higgins JP, Deeks JJ, Altman DG. Special topics in statis tics. In: Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. 5.0.2 ed. England: John Wiley & Sons Ltd, 2008,206
27. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br Med J, 2008,337:a1840
28. Camargo EG, Weinert LS, Lavinsky J, et al. The effect of aspirin on the antiproteinuric properties of enalapril in microalbuminuric type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. Diabetes Care, 2007, 30(7):e66
29. Camargo EG, Pedrini RO, Gross JL, et al. Lack of interference of aspirin in HbA1c measured by ion-exchange HPLC in type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. Clin Chim Acta, 2008,391(1-2):120-122
30. Chew EY, Williams GA, Burton TC, et al. Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16. Arch Ophthalmol, 1992,110(3):339-342
31. Chew EY, Klein ML, Murphy RP, et al. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Arch Ophthalmol, 1995,113(3):52-55
32. Contreras I, Reiser KM, Martinez N, et al. Effects of aspirin or basic amino acids on collagen cross-links and complications in NIDDM. Diabetes Care, 1997,20(5): 832-835
33. Gaede P, Hansen HP, Parving HH, et al. Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrol Dial Transplant, 2003,18(3):539-542
34. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 1998,351(9118):1755-1762
35. Hovens MM, Snoep JD, Groeneveld Y, et al. Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial. Diabetes Obes Metab, 2008,10(8): 668-674
36. Khajehdehi P, Roozbeh J, Mostafavi H. A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scand J Urol Nephrol, 2002,36(2):145-148
37. Kodama M, Yamasaki Y, Sakamoto K, et al. Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Thromb Res, 2000,97(4):239-245
38. Mork NL, Robertson RP. Effects of nonsteroidal antiinflammatory drugs in conventional dosage on glucose homeostasis in patients with diabetes. West J Med, 1983,139(1):46-49
39. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. Diabetes, 1989,38(4):491-498
40. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med, 1989,321(3):129-135
41. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology, 1991,98(5 Suppl):757-765
42. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA, 1992,268(10):1292-1300
43. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008,300(18):2134-2141
44. Prince RL, Larkins RG, Alford FP. The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects. Metab Clin Exp, 1981,30(3):293-298
45. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med, 2005,352(13):1293-1304
46. Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care, 2003,26(12):3264-3272
47. He JR, Ni AM, Zhang HG. Effect of captopril with aspirin on inceptive diabetic nephropathy. J Lanzhou Med Col (Chinese), 1995,25(2):31-33
48. Zhang W, Chen Y, Liu S, et al. The effect of aspirin to type 2 diabetic heart rate variability. J Shenyang Med Col (Chinese), 2002,4(1):28-30
49. Li WM, Xiong YG, Wang Z, et al. Clinical study on the prevention and treatment of NIDDM retinopathy with small dose aspirin. J Pharmac Prac (Chinese), 1998,16(6): 335-337
50. Li RL, Xie CC. Analysis of 30 diabetic patients treated with aspirin. J Handan Med Col (Chinese), 2000,13(4): 333
51. Lin L, Zhao YL, Shi FJ. Dynamic changes of IL-8 and CRP in senile type 2 diabetic patients after adminsteration of aspirin. China Trop Med (Chinese), 2006,6(4):645-646
52. Wang L, Zhao XW, Zhang Y, et al. Serum C-reactive protein levels in type 2 diabetes patients and effects of aspirin on C-reactive protein. J Shanxi Med Univ (Chinese), 2005,36(6):721-723
53. Dong AW. Clinical analysis of decrease of HbA1c level by aspirin on 55 diabetic patients. Pract Clin Med (Chinese), 2002,3(2):131-132
54. Jiang XZ, Gu Z, Zhou B, et al. Effects of aspirin on inflammatory factors of type 2 diabetes mellitus patients. Chin J New Drugs Clin Rem (Chinese), 2009,28(4): 297-300
55. Lu SQ. Clinical effectiveness of enalapril and aspirin on incipient diabetic nephropathy. Guangxi Med J (Chinese), 2004,26(2):186-188
56. Chen NH, Zhou P, He RH, et al. Relationship between change in content of platelet α-granule membrane protein and nephropathy in type 2 diabetic patients. Jiangsu Med J (Chinese), 2000,26(9):687-689
57. Field JB, Boyle C, Remer A. Effect of salicylate infusion on plasma-insulin and glucose tolerance in healthy persons and mild diabetics. Lancet, 1967,1(7501): 1191-1194
58. Robertson RP, Chen M. A role for prostaglandin E in defective insulin secretion and carbohydrate intolerance in diabetes mellitus. J Clin Invest, 1977,60(3):747-753
59. Bratusch-Marrain PR, Vierhapper H, Komjati M, et al. Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man. Diabetologia, 1985,28(9):671-676
60. Micossi P, Pontiroli AE, Baron SH, et al. Aspirin stimulates insulin and glucagon secretion and increases glucose tolerance in normal and diabetic subjects. Diabetes, 1978,27(12):1196-1204
61. Mubarak AA. Is low-dose aspirin a useful adjuvant therapy in the treatment of NIDDM? Diabet Med, 1997,14(5): 405-406
62. Strakosch CR, Jefferys DB, Keen H. Blockade of chlorpropamide alcohol flush by aspirin. Lancet, 1980,1(8165): 394-396
63. Skrha J, Hilgertova J, Svacina S, et al. Insulin receptors and glucose homeostasis in type 2 diabetics influenced by acetyl-salicylic acid treatment. Exp Clin Endocrinol, 1988,92(1):119-122
64. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest, 2002,109(10):1321-1326
65. Hopper AH, Tindall H, Davies JA. Effect of aspirin on glucose tolerance and insulin levels in patients with type 2 diabetes mellitus. Thromb Haemost, 1985,54(4):895
66. Vierhapper H, Bratusch-Marrain P, Waldhausl W, et al. Increased secretion of insulin but unchanged secretion of growth hormone in hyperglycaemic type II diabetics treated with acetyl-salicylic acid. Clin Endocrinol (Oxf), 1983,18(6):613-619
67. Tornvall G, Allgen LG. Acute effects of acetylsalicylic acid on blood glucose and insulin in non-insulin dependent diabetes. Acta Endocrinol Suppl (Copenh), 1980,239:6-8
68. Tian HM, Liang JZ, Li Y, et al. Effects of aspirin on plasma glucose and platelet for diabetic patients. Sichuan Med J (Chinese), 1989,10(4):206-207
69. Yu J, Wan J, Pan ZQ. Effects of fluvastatin and aspirin on C-reactive protein for old people with coronary heart disease and type 2 diabetes. Prac Geriat J (Chinese), 2008,22(3):232-234
70. Brass EP, Halter JB, Ensinck JW, et al. Effect of sodium salicylate on hormonal responses to hypoglycaemia in type II diabetics. Clin Endocrinol (Oxf), 1984,21(6): 649-655
71. Chen M, Robertson RP. Restoration of the acute insulin response by sodium salicylate. A glucose dose-related phenomenon. Diabetes, 1978,27(7):750-756
72. Gilgore SG, Drew WL, Rupp JJ. The effect of salicylate on plasma nonesterified fatty acids. Am J Med Sci, 1963,245:456-458
73. McRae JR, Metz SA, Robertson RP. A role for endogenous prostaglandins in defective glucose potentiation of nonglucose insulin secretagogues in diabetics. Metabolism, 1981,30(11):1065-1075
74. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol, 1971,231(25):232-235
75. Wu KK. Aspirin and salicylate: An old remedy with a new twist. Circulation, 2000,102(17):2022-2023
76. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature, 1998, 396(6706):77-80
77. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science, 1994,265(5174):956-959
78. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science, 2001,293(5535):1673-1677
79. Pierce JW, Read MA, Ding H, et al. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol, 1996,156(10):3961-3969
80. Xiao C, Giacca A, Lewis GF. The effect of high-dose sodium salicylate on chronically elevated plasma non-esterified fatty acid-induced insulin resistance and beta cell dysfunction. Am J Physiol Endocrinol Metab, 2009,297(5):E1205- 1211